Circassia Group Plc – CIR – Board Appointment

Circassia Group Plc – CIR – Board Appointment

Oxford, UK – 13 November 2020: Circassia Group plc (“Circassia” or “the Company”) (LSE: CIR), a leading medical device business focused on respiratory disease, today announces the appointment of Nicholas Mills as Non-Executive Director, effective 13 November 2020.

 

Nicholas is employed by Harwood Capital LLP, one of Circassia’s largest shareholders. Nicholas joined Harwood Capital LLP in 2019 after spending five years at Gabelli Asset Management in New York. He acted primarily as a Research Analyst covering the multi-industrial space and also gained experience in Merger Arbitrage strategies and marketing Closed End Funds. He has a Bachelor of Science Degree from Boston College’s Carroll School of Management. 

The following information in relation to Nicholas Mills is disclosed in accordance with Schedule 2(g) of the AIM Rules for Companies:  

Full name: Nicholas Harwood Bertram Mills 

Age: 30 

Shares held in Circassia: 60,000 shares in his own name, a further 70,000 shares are held jointly by Nicholas Mills and his two brothers and registered in the name of Harwood Capital LLP. 

  

Current directorships/partnerships

Past directorships/partnerships

Hargreaves Services PLC

Harwood Capital Management (Gibraltar) Limited

Growth Financial Services Limited

62 Pont Street (Freehold) Limited

 

None

Harwood Capital LLP (as investment adviser/manager), 1. Oryx International Growth Fund Limited 2. Harwood Capital LLP and 3. North Atlantic Smaller Companies Investment Trust plc collectively own 70,070,000 ordinary shares in Circassia representing 17.6% of Circassia’s current issued share capital.

There are no further disclosures to be made under Schedule 2(g) of the AIM Rules for Companies.

No Comments

Post a Comment